Galectin Therapeutics Inc. (NASDAQ:GALT - Get Free Report) CEO Joel Lewis sold 14,000 shares of the firm's stock in a transaction dated Friday, September 12th. The shares were sold at an average price of $6.36, for a total value of $89,040.00. Following the sale, the chief executive officer owned 832,592 shares in the company, valued at $5,295,285.12. This trade represents a 1.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Galectin Therapeutics Price Performance
GALT stock traded up $0.16 during mid-day trading on Friday, reaching $4.80. 282,644 shares of the company's stock were exchanged, compared to its average volume of 352,596. Galectin Therapeutics Inc. has a 12-month low of $0.73 and a 12-month high of $6.55. The stock's 50 day moving average is $3.90 and its 200 day moving average is $2.39. The company has a market cap of $307.49 million, a price-to-earnings ratio of -7.50 and a beta of 0.86.
Galectin Therapeutics (NASDAQ:GALT - Get Free Report) last announced its earnings results on Thursday, August 14th. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.04. On average, research analysts forecast that Galectin Therapeutics Inc. will post -0.73 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in GALT. Osaic Holdings Inc. grew its position in Galectin Therapeutics by 3.4% in the second quarter. Osaic Holdings Inc. now owns 1,265,384 shares of the company's stock worth $2,670,000 after acquiring an additional 41,968 shares during the period. Jane Street Group LLC purchased a new position in shares of Galectin Therapeutics during the 2nd quarter worth $1,580,000. Vivaldi Capital Management LP grew its holdings in shares of Galectin Therapeutics by 210.0% during the 2nd quarter. Vivaldi Capital Management LP now owns 172,443 shares of the company's stock worth $364,000 after purchasing an additional 116,815 shares during the period. Marshall Wace LLP acquired a new stake in shares of Galectin Therapeutics during the 2nd quarter worth about $64,000. Finally, XTX Topco Ltd raised its holdings in Galectin Therapeutics by 226.6% in the 2nd quarter. XTX Topco Ltd now owns 42,805 shares of the company's stock valued at $90,000 after buying an additional 29,699 shares during the period. 11.68% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
GALT has been the topic of several research analyst reports. HC Wainwright reiterated a "buy" rating and issued a $6.00 target price on shares of Galectin Therapeutics in a research report on Thursday, August 14th. Wall Street Zen raised Galectin Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, June 21st. One investment analyst has rated the stock with a Buy rating, According to MarketBeat.com, Galectin Therapeutics has a consensus rating of "Buy" and a consensus price target of $6.00.
Read Our Latest Analysis on Galectin Therapeutics
Galectin Therapeutics Company Profile
(
Get Free Report)
Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.
Featured Articles
Before you consider Galectin Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Galectin Therapeutics wasn't on the list.
While Galectin Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
